Human RANk (Receptor Activator of Nuclear Factor Kappa B) ELISA Kit (HUES03269)
- SKU:
- HUES03269
- Product Type:
- ELISA Kit
- Size:
- 96 Assays
- Uniprot:
- O14788
- Sensitivity:
- 0.09ng/mL
- Range:
- 0.16-10ng/mL
- ELISA Type:
- Sandwich
- Synonyms:
- RANK, TNFRSF11A, CD265, TRANCER, FEO, LOH18CR1, ODFR, OFE, OPTB7, OSTS, PDB2, NFKB Activator
- Reactivity:
- Human
- Sample Type:
- Serum, plasma and other biological fluids
- Research Area:
- Developmental Biology
Description
Human RANk (Receptor Activator of Nuclear Factor Kappa B) ELISA Kit
The Human Rank Receptor Activator of Nuclear Factor Kappa B ELISA Kit is a powerful tool for researchers studying the role of the Rank Receptor Activator of Nuclear Factor Kappa B in human biology. This kit is specifically designed for the accurate quantification of Rank Receptor Activator of Nuclear Factor Kappa B levels in serum, plasma, and cell culture supernatants.With its high sensitivity and specificity, this ELISA kit provides reliable and reproducible results, making it suitable for a wide range of research applications. The Rank Receptor Activator of Nuclear Factor Kappa B is a key protein involved in various biological processes, including bone metabolism, immune response, and cell differentiation.
By accurately measuring its levels, researchers can gain valuable insights into the mechanisms underlying these processes and potentially discover new therapeutic targets.Overall, the Human Rank Receptor Activator of Nuclear Factor Kappa B ELISA Kit is an essential tool for researchers looking to explore the role of this important protein in human health and disease.
| Assay type: | Sandwich |
| Format: | 96T |
| Assay time: | 4.5h |
| Reactivity: | Human |
| Detection Method: | Colormetric |
| Detection Range: | 0.16-10 ng/mL |
| Sensitivity: | 0.10 ng/mL |
| Sample Volume Required Per Well: | 100µL |
| Sample Type: | Serum, plasma and other biological fluids |
| Specificity: | This kit recognizes Human RANk in samples. No significant cross-reactivity or interference between Human RANk and analogues was observed. |
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human RANk. Standards or samples are added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human RANk and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human RANk, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by adding Stop Solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human RANk. The concentration of Human RANk in samples can be calculated by comparing the OD of the samples to the standard curve.
| UniProt Protein Function: | TNFSF11: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Homotrimer. Up-regulated by T-cell receptor stimulation. Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. Belongs to the tumor necrosis factor family. 3 isoforms of the human protein are produced by alternative splicing. |
| UniProt Protein Details: | Protein type:Membrane protein, integral Chromosomal Location of Human Ortholog: 13q14 Cellular Component: extracellular space; integral to plasma membrane; cytoplasm; extracellular region Molecular Function:cytokine activity; tumor necrosis factor receptor superfamily binding; tumor necrosis factor receptor binding Biological Process: ossification; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of osteoclast differentiation; cytokine and chemokine mediated signaling pathway; mammary gland epithelial cell proliferation; osteoclast differentiation; activation of JNK activity; positive regulation of corticotropin-releasing hormone secretion; positive regulation of homotypic cell-cell adhesion; activation of NF-kappaB transcription factor; calcium ion homeostasis; monocyte chemotaxis; positive regulation of protein kinase B signaling cascade; positive regulation of MAP kinase activity; organ morphogenesis; tumor necrosis factor-mediated signaling pathway; positive regulation of bone resorption; immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; positive regulation of T cell activation; protein homooligomerization; bone resorption Disease: Osteopetrosis, Autosomal Recessive 2 |
| NCBI Summary: | This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008] |
| UniProt Code: | O14788 |
| NCBI GenInfo Identifier: | 12643360 |
| NCBI Gene ID: | 8600 |
| NCBI Accession: | O14788. 1 |
| UniProt Secondary Accession: | O14788,O14723, Q96Q17, Q9P2Q3, |
| UniProt Related Accession: | O14788 |
| Molecular Weight: | 30,523 Da |
| NCBI Full Name: | Tumor necrosis factor ligand superfamily member 11 |
| NCBI Synonym Full Names: | tumor necrosis factor (ligand) superfamily, member 11 |
| NCBI Official Symbol: | TNFSF11 |
| NCBI Official Synonym Symbols: | ODF; OPGL; sOdf; CD254; OPTB2; RANKL; TRANCE; hRANKL2 |
| NCBI Protein Information: | tumor necrosis factor ligand superfamily member 11; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand |
| UniProt Protein Name: | Tumor necrosis factor ligand superfamily member 11 |
| UniProt Synonym Protein Names: | Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; Receptor activator of nuclear factor kappa-B ligand; RANKL; TNF-related activation-induced cytokine; TRANCE; CD_antigen: CD254Cleaved into the following 2 chains:Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form |
| UniProt Gene Name: | TNFSF11 |
| UniProt Entry Name: | TNF11_HUMAN |
As the OD values of the standard curve may vary according to the conditions of the actual assay performance (e. g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.
| Concentration (ng/mL) | O.D | Average | Corrected |
| 10 | 2.263 2.293 | 2.278 | 2.207 |
| 5 | 1.53 1.548 | 1.539 | 1.468 |
| 2.5 | 0.881 0.853 | 0.867 | 0.796 |
| 1.25 | 0.424 0.46 | 0.442 | 0.371 |
| 0.63 | 0.246 0.226 | 0.236 | 0.165 |
| 0.32 | 0.176 0.154 | 0.165 | 0.094 |
| 0.16 | 0.117 0.123 | 0.12 | 0.049 |
| 0 | 0.066 0.076 | 0.071 | -- |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, mid range and high level Human RANk were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, mid range and high level Human RANk were tested on 3 different plates, 20 replicates in each plate.
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.55 | 0.98 | 3.38 | 0.58 | 0.96 | 3.28 |
| Standard deviation | 0.03 | 0.05 | 0.16 | 0.04 | 0.05 | 0.11 |
| C V (%) | 5.45 | 5.10 | 4.73 | 6.90 | 5.21 | 3.35 |
Recovery
The recovery of Human RANk spiked at three different levels in samples throughout the range of the assay was evaluated in various matrices.
| Sample Type | Range (%) | Average Recovery (%) |
| Serum (n=5) | 86-101 | 93 |
| EDTA plasma (n=5) | 91-107 | 98 |
| Cell culture media (n=5) | 93-107 | 99 |
Linearity
Samples were spiked with high concentrations of Human RANk and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.
| Serum (n=5) | EDTA plasma (n=5) | Cell culture media (n=5) | ||
| 1:2 | Range (%) | 93-108 | 93-104 | 94-106 |
| Average (%) | 100 | 98 | 99 | |
| 1:4 | Range (%) | 89-104 | 85-95 | 84-95 |
| Average (%) | 95 | 90 | 89 | |
| 1:8 | Range (%) | 86-101 | 81-91 | 88-101 |
| Average (%) | 92 | 86 | 95 | |
| 1:16 | Range (%) | 90-106 | 82-93 | 84-97 |
| Average (%) | 97 | 87 | 91 |
An unopened kit can be stored at 4°C for 1 month. If the kit is not used within 1 month, store the items separately according to the following conditions once the kit is received.
| Item | Specifications | Storage |
| Micro ELISA Plate(Dismountable) | 8 wells ×12 strips | -20°C, 6 months |
| Reference Standard | 2 vials | |
| Concentrated Biotinylated Detection Ab (100×) | 1 vial, 120 µL | |
| Concentrated HRP Conjugate (100×) | 1 vial, 120 µL | -20°C(shading light), 6 months |
| Reference Standard & Sample Diluent | 1 vial, 20 mL | 4°C, 6 months |
| Biotinylated Detection Ab Diluent | 1 vial, 14 mL | |
| HRP Conjugate Diluent | 1 vial, 14 mL | |
| Concentrated Wash Buffer (25×) | 1 vial, 30 mL | |
| Substrate Reagent | 1 vial, 10 mL | 4°C(shading light) |
| Stop Solution | 1 vial, 10 mL | 4°C |
| Plate Sealer | 5 pieces | |
| Product Description | 1 copy | |
| Certificate of Analysis | 1 copy |
- Set standard, test sample and control (zero) wells on the pre-coated plate and record theirpositions. It is recommended to measure each standard and sample in duplicate. Note: addall solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensuresolutions do not foam when adding to the wells.
- Aliquot 100µl of standard solutions into the standard wells.
- Add 100µl of Sample / Standard dilution buffer into the control (zero) well.
- Add 100µl of properly diluted sample (serum, plasma, tissue homogenates and otherbiological fluids) into test sample wells.
- Cover the plate with the sealer provided in the kit and incubate for 90 min at 37°C.
- Aspirate the liquid from each well, do not wash. Immediately add 100µL of BiotinylatedDetection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37°C.
- Aspirate or decant the solution from the plate and add 350µL of wash buffer to each welland incubate for 1-2 minutes at room temperature. Aspirate the solution from each well andclap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplatewasher can be used in this step and other wash steps.
- Add 100µL of HRP Conjugate working solution to each well. Cover with a plate seal andincubate for 30 min at 37°C.
- Aspirate or decant the solution from each well. Repeat the wash process for five times asconducted in step 7.
- Add 90µL of Substrate Reagent to each well. Cover with a new plate seal and incubate forapproximately 15 min at 37°C. Protect the plate from light. Note: the reaction time can beshortened or extended according to the actual color change, but not by more than 30min.
- Add 50 µL of Stop Solution to each well. Note: Adding the stop solution should be done inthe same order as the substrate solution.
- Determine the optical density (OD value) of each well immediately with a microplate readerset at 450 nm.
Related Products
Human RANk (Receptor Activator of Nuclear Factor Kappa B) CLIA Kit (HUES01247)
Mouse RANk (Receptor Activator of Nuclear Factor Kappa B) CLIA Kit (MOES00353)
Rat RANk (Receptor Activator of Nuclear Factor Kappa B) CLIA Kit (RTES00090)
Human RANkL (Receptor Activator of Nuclear Factor Kappa B Ligand) CLIA Kit (HUES00796)
